Gotowe bibliografie tematyczne / Anti-breast cancer drug

Spis treści

  1. Artykuły w czasopismach
  2. Rozprawy doktorskie
  3. Książki
  4. Części książek
  5. Streszczenia konferencji
  6. Raporty organizacyjne

Gotowa bibliografia na temat „Anti-breast cancer drug”

Autor: Grafiati
Data publikacji: 2 czerwca 2025
Data aktualizacji: 31 lipca 2025

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Anti-breast cancer drug”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "Anti-breast cancer drug"

1

Lou, Song. "Multifunctional Nanotherapeutics for Drug-Resistant Breast Cancer." Bioequivalence & Bioavailability International Journal 6, no. 1 (2022): 1–6. http://dx.doi.org/10.23880/beba-16000160.

Pełny tekst źródła
Streszczenie:
Tumors are inherently resilient and always develop drug-resistance, leading to poor patient therapy effect. With the developing of sophisticated analytical tools, some novel strategy on improving targeting of anti-cancer delivery is developed to better thwart drug-resistance. This report demonstrates a multilayered nano-system to serve as a multifunctional platform for the treatment of drug-resistant breast cancers. This nano-system is composed of a poly (lactic-co-glycolic acid) core, a liposome second layer, and a hyaluronic acid outmost layer. The different types of drug, loaded in differen
Style APA, Harvard, Vancouver, ISO itp.
2

Hussain, Tanveer, Seeram Ramakrishna, and Sharjeel Abid. "Nanofibrous drug delivery systems for breast cancer: a review." Nanotechnology 33, no. 10 (2021): 102001. http://dx.doi.org/10.1088/1361-6528/ac385c.

Pełny tekst źródła
Streszczenie:
Abstract Breast cancer is the most common type of cancer among women. Breast-conserving surgery (BCS) is one of the preferred approaches for treating non-invasive or early-stage breast cancers. However, local-regional recurrence (LRR) is one of the critical risk factors after BCS. As many as 10%–20% of BCS cases may show LRR within 5 years and almost 50% within 10 years after surgery. Radiation therapy is one of the preferred treatments used to prevent LRR after BCS. However, because of possible side-effects of radiation therapy, targeted drug delivery systems (DDS) based on nanofibers loaded
Style APA, Harvard, Vancouver, ISO itp.
3

Cai, Alvan, Yuan Chen, Lily S. Wang, John K. Cusick, and Yihui Shi. "Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer." Cancers 16, no. 15 (2024): 2635. http://dx.doi.org/10.3390/cancers16152635.

Pełny tekst źródła
Streszczenie:
HER2 (human epidermal growth factor receptor 2) is highly expressed in a variety of cancers, including breast, lung, gastric, and pancreatic cancers. Its amplification is linked to poor clinical outcomes. At the genetic level, HER2 is encoded by the ERBB2 gene (v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2), which is frequently mutated or amplified in cancers, thus spurring extensive research into HER2 modulation and inhibition as viable anti-cancer strategies. An impressive body of FDA-approved drugs, including anti-HER2 monoclonal antibodies (mAbs), antibody–drug conjugates
Style APA, Harvard, Vancouver, ISO itp.
4

Bernatsky, S., R. Ramsey-Goldman, M. Petri, et al. "Breast cancer in systemic lupus." Lupus 26, no. 3 (2016): 311–15. http://dx.doi.org/10.1177/0961203316664595.

Pełny tekst źródła
Streszczenie:
Objective There is a decreased breast cancer risk in systemic lupus erythematosus (SLE) versus the general population. We assessed a large sample of SLE patients, evaluating demographic and clinical characteristics and breast cancer risk. Methods We performed case-cohort analyses within a multi-center international SLE sample. We calculated the breast cancer hazard ratio (HR) in female SLE patients, relative to demographics, reproductive history, family history of breast cancer, and time-dependent measures of anti-dsDNA positivity, cumulative disease activity, and drugs, adjusted for SLE durat
Style APA, Harvard, Vancouver, ISO itp.
5

Ton Tai, Dinh Xuan, Le Thi Huong, Tran Hoang Mai, Vu Manh Hung, Nguyen Thi Huyen, and Bui Thanh Tung. "Screening in silico the human epidermal growth factor receptor-2inhibitory effect of isoflavones by molecular docking method for their potential use in breast cancer." Ministry of Science and Technology, Vietnam 65, no. 2 (2023): 47–53. http://dx.doi.org/10.31276/vjste.65(2).47-53.

Pełny tekst źródła
Streszczenie:
Isoflavones are secondary phenolic metabolites found in most legumes. These compounds have important pharmacological significance such as anti-osteoporosis, anti-aging, and anti-cancer properties. Breast cancer is one of the most common cancers in women worldwide. Human epidermal growth factor receptor-2 (HER2) is an important target in breast cancer treatment. In this study, we evaluated the ability of sixty isoflavones compounds to inhibit the HER2 enzyme for their potential use in breast cancer treatments by the molecular docking method. Molecular docking was done by Autodock vina software.
Style APA, Harvard, Vancouver, ISO itp.
6

Samuel, Samson, Elizabeth Varghese, Peter Kubatka, Chris Triggle, and Dietrich Büsselberg. "Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer." Biomolecules 9, no. 12 (2019): 846. http://dx.doi.org/10.3390/biom9120846.

Pełny tekst źródła
Streszczenie:
Interest has grown in studying the possible use of well-known anti-diabetic drugs as anti-cancer agents individually or in combination with, frequently used, chemotherapeutic agents and/or radiation, owing to the fact that diabetes heightens the risk, incidence, and rapid progression of cancers, including breast cancer, in an individual. In this regard, metformin (1, 1-dimethylbiguanide), well known as ‘Glucophage’ among diabetics, was reported to be cancer preventive while also being a potent anti-proliferative and anti-cancer agent. While meta-analysis studies reported a lower risk and incid
Style APA, Harvard, Vancouver, ISO itp.
7

Li, Jiaying, Guowei Zhang, and Hongxia Yang. "Optimal modeling of anti breast cancer drug candidates." Highlights in Science, Engineering and Technology 45 (April 18, 2023): 350–60. http://dx.doi.org/10.54097/hset.v45i.7573.

Pełny tekst źródła
Streszczenie:
As breast cancer is one of the most common cancers with high mortality rate in the world, this paper studies the optimal screening of anti-breast cancer candidate drugs. First, the data of 729 compound molecular descriptors are preprocessed, rough cleaned and filtered to 253, and then the cluster feature tree and correlation analysis are used to further reduce the dimension of data redundancy information, and 29 representative molecular descriptors are screened. In order to determine the importance and significance variables affecting the activity of compounds, the preliminary results were obt
Style APA, Harvard, Vancouver, ISO itp.
8

Zhang, Ya-Zhou, Hai-Lin Liu, Qian-Song He, and Zhi Xu. "The In Vitro Anticancer Activity and Potential Mechanism of Action of 1-[(1R,2S)-2-fluorocyclopropyl]Ciprofloxacin-(4-methyl/phenyl/benzyl-3- aryl)-1,2,4-triazole-5(4H)-thione Hybrids." Current Topics in Medicinal Chemistry 20, no. 16 (2020): 1493–98. http://dx.doi.org/10.2174/1568026620666200310123723.

Pełny tekst źródła
Streszczenie:
Aims: Development of 1-[(1R, 2S)-2-fluorocyclopropyl]ciprofloxacin-1,2,4-triazole-5(4H)- thione hybrids as potential dual-acting mechanism anticancer agent to overcome the drug resistance. Background: Chemotherapy is an essential tool for the treatment of lung and female breast cancers, and numerous anticancer agents have been launched for this purpose. However, the clinical outcomes of chemotherapy are usually far from satisfactory due to the side effects and resistance to chemotherapeutic drugs. Thus, it is urgent to develop novel anti-lung and anti-breast cancer agents. Background: Chemothe
Style APA, Harvard, Vancouver, ISO itp.
9

Rajagopal, Kalirajan, Anandarajagopal Kalusalingam, Anubhav Raj Bharathidasan, et al. "In Silico Drug Design of Anti-Breast Cancer Agents." Molecules 28, no. 10 (2023): 4175. http://dx.doi.org/10.3390/molecules28104175.

Pełny tekst źródła
Streszczenie:
Cancer is a condition marked by abnormal cell proliferation that has the potential to invade or indicate other health issues. Human beings are affected by more than 100 different types of cancer. Some cancer promotes rapid cell proliferation, whereas others cause cells to divide and develop more slowly. Some cancers, such as leukemia, produce visible tumors, while others, such as breast cancer, do not. In this work, in silico investigations were carried out to investigate the binding mechanisms of four major analogs, which are marine sesquiterpene, sesquiterpene lactone, heteroaromatic chalcon
Style APA, Harvard, Vancouver, ISO itp.
10

Cao, Yi, Yunjin Li, Ruijie Liu, Jianhua Zhou, and Kuansong Wang. "Preclinical and Basic Research Strategies for Overcoming Resistance to Targeted Therapies in HER2-Positive Breast Cancer." Cancers 15, no. 9 (2023): 2568. http://dx.doi.org/10.3390/cancers15092568.

Pełny tekst źródła
Streszczenie:
The amplification of epidermal growth factor receptor 2 (HER2) is associated with a poor prognosis and HER2 gene is overexpressed in approximately 15–30% of breast cancers. In HER2-positive breast cancer patients, HER2-targeted therapies improved clinical outcomes and survival rates. However, drug resistance to anti-HER2 drugs is almost unavoidable, leaving some patients with an unmet need for better prognoses. Therefore, exploring strategies to delay or revert drug resistance is urgent. In recent years, new targets and regimens have emerged continuously. This review discusses the fundamental
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Rozprawy doktorskie na temat "Anti-breast cancer drug"

1

Yaourtis, Andria. "Innate and anti-cancer drug-induced morphological changes in the human breast cancer cell line MDA-MB-231." Thesis, The University of Sydney, 2021. https://hdl.handle.net/2123/26409.

Pełny tekst źródła
Streszczenie:
Phenotypic changes in tumour cells is a well-established phenomenon and can happen either naturally or in response to a drug. Such changes in phenotype are often accompanied with changes in the behaviour of tumour cells, including growth, proliferation, as well as their migratory and invasive capacity. Phenotypic changes can, therefore, impact the aggressiveness of the tumour cell and dictate their metastatic potential. Thus, it is of utmost importance to fully understand and characterise phenotypic changes in tumour cells in order to better understand tumour progression and identify therapeut
Style APA, Harvard, Vancouver, ISO itp.
2

Guardia, Valenzuela Cristina 1990. "Cancer-associated fibroblasts and response to anti-HER2 monoclonal antibodies in breast cancer." Doctoral thesis, Universitat Pompeu Fabra, 2019. http://hdl.handle.net/10803/668327.

Pełny tekst źródła
Streszczenie:
El cáncer de mama HER2-positivo es un subtipo muy agresivo. El desarrollo de terapias anti-diana HER2, particularmente el anticuerpo monoclonal (Mab) trastuzumab, supuso una mejora significativa en el pronóstico de esta enfermedad. De manera más reciente, otro Mab llamado pertuzumab, ha mejorado todavía más la eficiencia de trastuzumab. Aún y así, no todas las pacientes se beneficiarán de esta combinación de mAbs. Una proporción de estas pacientes no se beneficiarán de estas terapias anti-HER2, y fallecerán a causa de la presencia o el desarrollo de mecanismos de resistencia. Los tumores con
Style APA, Harvard, Vancouver, ISO itp.
3

Lovitt, Carrie Jade. "Exploring Breast Cancer Drug Targets in the Third Dimension with Imaging." Thesis, Griffith University, 2014. http://hdl.handle.net/10072/367232.

Pełny tekst źródła
Streszczenie:
This project utilises innovative methodology to evaluate the suitability of novel three-dimensional (3D) cell culture models for investigating anti-cancer drug activity. 3D cell culture methodology was utilised as this in vitro approach is considered to recapitulate the in vivo conditions more accurately than two-dimensional (2D) monolayer cell culture. Two separate 3D cell culture model formats were developed which are amenable to automated liquid handling systems, and a variety of instruments for total well fluorescence and confocal imaging. The first 3D cell culture assay developed was in a
Style APA, Harvard, Vancouver, ISO itp.
4

Bonzi, Gwénaëlle A. M. "Novel polysaccharide anti-tumour drug delivery system for active targeting and controlled release to breast cancer bone metastases." Doctoral thesis, Università degli studi di Padova, 2014. http://hdl.handle.net/11577/3423664.

Pełny tekst źródła
Streszczenie:
ABSTRACT In the late stage of the disease, breast cancer patients often develop bone metastases, a major cause of cancer-related death among women worldwide. The common treatment currently used clinically includes the anti-neoplastic agent paclitaxel combined with the bisphosphonate alendronate. Paclitaxel is an anti-neoplastic drug which cytotoxic effect is mainly attributed to its ability to promote the assembly of microtubules as well as prevent the depolymerisation of these microtubules. Stabilization of the microtubule networks stops mitotic functions that, in sequence, blocks cell div
Style APA, Harvard, Vancouver, ISO itp.
5

Wan, Xiao. "Development of advanced three-dimensional tumour models for anti-cancer drug testing." Thesis, University of Oxford, 2014. http://ora.ox.ac.uk/objects/uuid:5342fe46-c676-4fe8-8b6e-96d17a18d17d.

Pełny tekst źródła
Streszczenie:
Animal testing is still the common method to test the efficacy of new drugs, but tissue engineered in vitro models are becoming more acceptable for replacing and reducing animal testing in anti-cancer drug screening by developing in vitro three-dimensional (3D) tumour models for anti-cancer drug testing. In this study, three-dimensional (3D) culture methods were developed to mimic the tumour microenvironment. 3D culturing is to seed, maintain and expand cultured cells in three-dimensional space, in contrast to the traditional two-dimensional (2D) method in which the cells attach to the bottom
Style APA, Harvard, Vancouver, ISO itp.
6

Leonardi, Antonio. "Design, synthesis of substituted purines, phenylpyrrolidine derivatives, cyclic and acyclic bis (p-nitrobenzenesulfonamides), and in vitro anti-cancer activity against lung, breast and prostate cell lines." Doctoral thesis, Università di Catania, 2012. http://hdl.handle.net/10761/1175.

Pełny tekst źródła
Streszczenie:
Al momento sono stati classificati più di 100 forme di cancro secondo il tipo di cellula inizialmente affetta. Le patologie tumorali sono caratterizzate da una crescita cellulare incontrollata che porta alla formazione di grumi o masse di tessuto che danneggiano l organismo. Lo sviluppo di nuovi farmaci antitumorali è una delle attività prioritarie nell'ambito della ricerca chimico-farmaceutica, non solo per l alta incidenza ma anche per i numerosi inconvenienti legati ai farmaci in uso. Il progetto di ricerca è stato indirizzato al disegno, sintesi e valutazione biologica di nuovi farmaci ant
Style APA, Harvard, Vancouver, ISO itp.
7

Dubois, Clémence. "Optimisation du traitement du cancer du sein Triple-Négatif : développement des modèles de culture cellulaire en trois dimensions, efficacité de l'Olaparib (anti-PARP1) en combinaison avec la radiothérapie et chimiorésistance instaurée par les protéines Multi Drug Résistance." Thesis, Université Clermont Auvergne‎ (2017-2020), 2018. http://www.theses.fr/2018CLFAS018/document.

Pełny tekst źródła
Streszczenie:
Le cancer du sein est une maladie complexe et difficile à caractériser. Parmi les différents sous-types moléculaires, les tumeurs du sein Triple-Négatives (TN) sont particulièrement agressives et de mauvais pronostic. Elles sont caractérisées par une absence d’expression des récepteurs aux œstrogènes (ER), à la progestérone (PR), l’absence de surexpression du récepteur Human Epidermal growth factor 2 (HER2) et de fréquentes mutations sur les gènes BRCA1/2 (profil « BRCAness »). En absence de thérapies ciblées efficaces, de nombreux traitements ciblés notamment les inhibiteurs de poly-ADP-ribos
Style APA, Harvard, Vancouver, ISO itp.
8

Khubieh, J. "Immunoassay of 4-Hydroxyandrostenedione, a new anti-cancer agent." Thesis, University of Surrey, 1989. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.234454.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Diaz-Cruz, Edgar S. "Interrelationships between aromatase and cyclooxygenase-2 and their role in the autocrine and paracrine mechanisms in breast cancer." Connect to resource, 2005. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1117117648.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Oechsle, Crystal Mae. "The Use and Enhancement of Anti-Cancer Vaccine Therapy with Low-Toxicity Drugs for the Treatment of HER2 Positive Breast Cancer." Kent State University / OhioLINK, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=kent1561121654968093.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Książki na temat "Anti-breast cancer drug"

1

Julia, Gee, Nicholson Robert I, and SpringerLink (Online service), eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets. Springer Netherlands, 2009.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Hiscox, Stephen, Julia Gee, and Robert I. Nicholson, eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer. Springer Netherlands, 2009. http://dx.doi.org/10.1007/978-1-4020-8526-0.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Hiscox, Stephen, Julia Gee, and Robert I. Nicholson. Therapeutic Resistance to Anti-hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets. Hiscox Stephen Gee Julia Nicholson Robert I, 2010.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Gluckman, Sir Peter, Mark Hanson, Chong Yap Seng, and Anne Bardsley. Guidelines for breastfeeding and weaning. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780198722700.003.0038.

Pełny tekst źródła
Streszczenie:
Breastfeeding provides almost all of the nutrient requirements for the growing infant to the age of 6 months. Complementary foods rich in iron should be introduced by 6 months, but continued breastfeeding past this point is still beneficial to the infant. It is also beneficial for the mother, reducing postpartum weight retention and lowering the risk of breast and other gynaecological cancers. Breastfeeding women have increased energy requirements to meet the energy costs of milk production. Some specific nutrient requirements also increase during lactation. Excess alcohol consumption, smoking
Style APA, Harvard, Vancouver, ISO itp.

Części książek na temat "Anti-breast cancer drug"

1

Priya, R. Arul, K. Saravanan, and Chukwuebuka Egbuna. "Phytochemical Investigation and Evaluation of Anti-Breast Cancer Activity of Chloroform Extract of Tagetes erecta." In Drug Development for Cancer and Diabetes. Apple Academic Press, 2020. http://dx.doi.org/10.1201/9780429330490-13.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Domenici, Giacomo, Gonçalo Trindade, Marta F. Estrada, et al. "Patient-Derived Breast Cancer Tissue Cultures for Anti-Endocrine Drug Assays." In Methods in Molecular Biology. Springer US, 2022. http://dx.doi.org/10.1007/978-1-0716-2513-2_2.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Gao, Wentao, Ziyi Huang, Hao Zhang, and Jianfeng Lu. "Anti-breast Cancer Drug Design and ADMET Prediction of ERa Antagonists Based on QSAR Study." In Intelligent Computing Theories and Application. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-13829-4_3.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Nagar, Swati. "Pharmacokinetics of Anti-Cancer Drugs Used in Breast Cancer Chemotherapy." In Chemo Fog. Springer New York, 2010. http://dx.doi.org/10.1007/978-1-4419-6306-2_16.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Natarajan, Karthika, Maria R. Baer, and Douglas D. Ross. "Role of Breast Cancer Resistance Protein (BCRP, ABCG2) in Cancer Outcomes and Drug Resistance." In Resistance to Targeted Anti-Cancer Therapeutics. Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-09801-2_3.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Harris, Randall E. "Epidemiology of Breast Cancer and Nonsteroidal Anti-Inflammatory Drugs." In COX-2 Blockade in Cancer Prevention and Therapy. Humana Press, 2003. https://doi.org/10.1007/978-1-59259-302-6_4.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Kaye, S. B. "The Multi-Drug Resistance Phenotype and its Reversal by Drugs (with Special Emphasis on Anti-Oestrogens)." In Endocrine Therapy of Breast Cancer V. Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-77662-5_6.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Hyder, Salman M., Benford Mafuvadze, and Cynthia Besch-Williford. "Novel Anti-angiogenic Therapies Using Naturally Occurring and Synthetic Drugs to Combat Progestin-Dependent Breast Cancer." In Cell and Molecular Biology of Breast Cancer. Humana Press, 2013. http://dx.doi.org/10.1007/978-1-62703-634-4_7.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Abou-Issa, Hussein M., Galal A. Alshafie, and Randall E. Harris. "Chemoprevention of Breast Cancer by Nonsteroidal Anti-Inflammatory Drugs and Selective COX-2 Blockade in Animals." In COX-2 Blockade in Cancer Prevention and Therapy. Humana Press, 2003. https://doi.org/10.1007/978-1-59259-302-6_6.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Jha, Tarun, Nilanajn Adhikari, Amit Kumar Halder, and Achintya Saha. "Ligand- and Structure-Based Drug Design of Non-Steroidal Aromatase Inhibitors (NSAIs) in Breast Cancer." In Quantitative Structure-Activity Relationships in Drug Design, Predictive Toxicology, and Risk Assessment. IGI Global, 2015. http://dx.doi.org/10.4018/978-1-4666-8136-1.ch011.

Pełny tekst źródła
Streszczenie:
Aromatase is a multienzyme complex overexpressed in breast cancer and responsible for estrogen production. It is the potential target for designing anti-breast cancer drugs. Ligand and Structure-Based Drug Designing approaches (LBDD and SBDD) are involved in development of active and more specific Nonsteroidal Aromatase Inhibitors (NSAIs). Different LBDD and SBDD approaches are presented here to understand their utility in designing novel NSAIs. It is observed that molecules should possess a five or six membered heterocyclic nitrogen containing ring to coordinate with heme portion of aromatase
Style APA, Harvard, Vancouver, ISO itp.

Streszczenia konferencji na temat "Anti-breast cancer drug"

1

Marshall, Lauren, Isabel Löwstedt, Paul Gatenholm, and Joel Berry. "Prevascularized, Co-Culture Model for Breast Cancer Drug Development." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80409.

Pełny tekst źródła
Streszczenie:
The objective of this study was to create 3D engineered tissue models to accelerate identification of safe and efficacious breast cancer drug therapies. It is expected that this platform will dramatically reduce the time and costs associated with development and regulatory approval of anti-cancer therapies, currently a multi-billion dollar endeavor [1]. Existing two-dimensional (2D) in vitro and in vivo animal studies required for identification of effective cancer therapies account for much of the high costs of anti-cancer medications and health insurance premiums borne by patients, many of w
Style APA, Harvard, Vancouver, ISO itp.
2

"PAMAM Dendrimers as anti-HER2 Positive Breast Cancer Treatment." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0176.

Pełny tekst źródła
Streszczenie:
Background: Poly (amidoamine) dendrimers (PAMAMs) are widely used in drug delivery systems and gene transfection as drug carriers. They also exert several biological effects like modulating gene expression, particularly EGFR (ErbB1) signaling pathway, which raises the question of whether these polymers can also inhibit the phosphorylation of HER2 (ErbB2) in breast cancer. However, this area hasn’t been investigated before. Methods: In this study, we evaluated the anticancer effects of different generations and surface chemistries of PAMAMs on HER2 positive breast cancer cells (SkBr3 and ZR-75
Style APA, Harvard, Vancouver, ISO itp.
3

Lichtenfels, Martina, Camila Alves Silva, Caroline Brunetto Farias, Alessandra Borba Anton Souza, and Antônio Luiz Frasson. "TIN VITRO BREAST CANCER CHEMORESISTANCE TEST." In Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1058.

Pełny tekst źródła
Streszczenie:
Introduction: Tumor resistance is the main cause of treatment failure leading to cancer progression and is classified into intrinsic and acquired resistance. Intrinsic resistance is related to a preexisting condition and acquired resistance is induced by a drug. Some methods are already available worldwide to assess drug resistance, however, in Brazil no in vitro chemoresistance test for cancer is validated for clinic use. Objectives: The aim of our study was to validate the in vitro chemoresistance test Chemobiogram for the drugs used in breast cancer (BC) treatment. An incomplete response to
Style APA, Harvard, Vancouver, ISO itp.
4

Al-Atieh, Noor, Salma Ahmad, Hanan Nazar, and Allal Ouhtit. "Anti-cancer properties of Microalgae (T1) Extract in Breast Cancer Cell Lines." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2021. http://dx.doi.org/10.29117/quarfe.2021.0154.

Pełny tekst źródła
Streszczenie:
Breast cancer (BC), a worldwide health issue, is the most common malignant cancer in women in Gulf region, including the State of Qatar. Unfortunately, malignant tumors has the capability to metastasis, which involves both migration and invasion of cancer cells which are the most threatening aspects of cancer (McSherry et al., 2007). Consequently, researchers have concentrated on Complementary and Alternative medicine (CAM) modalities, as conventional medicine has been facing various challenges such as; poor understanding of the mechanisms with BC proliferation and invasion within various grou
Style APA, Harvard, Vancouver, ISO itp.
5

Xiao, Weiqiang, Xiaoli Chai, Shengji Jiang, and Zhibai Huang. "Optimization modeling of anti breast cancer drug candidates based on data mining." In International Symposium on Robotics, Artificial Intelligence, and Information Engineering (RAIIE 2022), edited by Johan Debayle. SPIE, 2022. http://dx.doi.org/10.1117/12.2658192.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Hu, Xinxin, and Jiayao Lv. "Optimized modeling of anti-breast cancer drug candidates based on machine learning." In Second International Conference on Biomedical and Intelligent Systems (IC-BIS2023), edited by Ming Chen and Gangmin Ning. SPIE, 2023. http://dx.doi.org/10.1117/12.2687762.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Jácome, María Amalia, Ana López-Cheda, and Samuel Saavedra. "Estimation of Cardiotoxicity in Breast Cancer Patients Using Presmoothing and Cure Models." In VII Congreso XoveTIC: impulsando el talento científico. Servizo de Publicacións. Universidade da Coruña, 2024. https://doi.org/10.17979/spudc.9788497498913.65.

Pełny tekst źródła
Streszczenie:
Breast cancer is the most common type of cancer for women. Nowadays, the side-effects that some treatments against this type of cancer can be a major problem. One example of this is HER2-positive breast cancer patients. Patients are prescribed trastuzumab, a drug with anti-tumour efficacy, but this treatment can cause various undesirable effects such as heart problems, known as cardiotoxicity. With the aim of improving the quality of life of those affected, the question is clear: what is the likelihood of suffering cardiotoxicity? In this work, this probability is estimated using a new approac
Style APA, Harvard, Vancouver, ISO itp.
8

Rudkouskaya, Alena, Jason T. Smith, Marien Ochoa, Xavier Intes, and Margarida Barroso. "Quantification of anti-HER2 drug uptake into human breast cancer cells using fluorescence lifetime FRET imaging." In Visualizing and Quantifying Drug Distribution in Tissue IV, edited by Conor L. Evans and Kin Foong Chan. SPIE, 2020. http://dx.doi.org/10.1117/12.2544429.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Barbosa, Ana Carolina Silva, Cristiano Augusto Andrade de Resende, Henrique Carvalho Rocha, and Andreza Karine de Barros Almeida Souto. "Case report: sinusoidal obstruction syndrome post-treatment with trastuzumab emtansine in breast cancer." In Brazilian Breast Cancer Symposium 2024. Mastology, 2024. http://dx.doi.org/10.29289/259453942024v34s1104.

Pełny tekst źródła
Streszczenie:
Objective: Trastuzumab emtansine (T-DM1) is an anti-HER2 antibody-drug conjugate indicated for the treatment of HER2- positive breast cancer. One of the most severe adverse events reported with T-DM1 is hepatotoxicity. More recently, some cases of noncirrhotic portal hypertension have been described in patients with long-term T-DM1. The underlying liver condition is usually sinusoidal obstruction syndrome. Methodology: Here, we present the case of a patient with early-stage HER2-positive breast cancer who received adjuvant T-DM1 and developed hepatotoxicity due to this condition. Results: We r
Style APA, Harvard, Vancouver, ISO itp.
10

Mladenović, Milan P., Nevena M. Tomašević, Sanja Lj Matić, Tamara M. Mladenović, and Rino Ragno. "Computer-aided design of new drugs against breast cancer." In 2nd International Conference on Chemo and Bioinformatics. Institute for Information Technologies, University of Kragujevac, 2023. http://dx.doi.org/10.46793/iccbi23.641m.

Pełny tekst źródła
Streszczenie:
Computational medicinal chemistry, if used properly and in accordance with the available experimental data, may provide significant support to rational drug design. Herein, an overview of the computational approaches that have been applied to an estrogen receptor α (ERα) and endowed in the rational design of pM ERα antagonists with profound anti-breast cancer activity either in vitro or in vivo, will be presented. ERα is a 17β-estradiol inducible transcriptional regulator that initiates the RNA polymerase II-dependent transcriptional machinery, pointed for breast cancer (BC) development via ei
Style APA, Harvard, Vancouver, ISO itp.

Raporty organizacyjne na temat "Anti-breast cancer drug"

1

Gaczynska, Maria E. Molecular Characteristics of Multicorn, A New Large Proteolytic Assembly and Potential Anti-Cancer Drug Target, in Human Breast Cancer Cells. Defense Technical Information Center, 2003. http://dx.doi.org/10.21236/ada418003.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Yen, Timothy J. Validate Mitotic Checkpoint and Kinetochore Motor Proteins in Breast Cancer Cells as Targets for the Development of Novel Anti-Mitotic Drugs. Defense Technical Information Center, 2005. http://dx.doi.org/10.21236/ada439249.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Yen, Timothy J. Validate Mitotic Checkpoint and Kinetochore Motor Proteins in Breast Cancer Cells as Targets for the Development of Novel Anti-Mitotic Drugs. Defense Technical Information Center, 2002. http://dx.doi.org/10.21236/ada407481.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Yen, Timothy J. Validate Mitotic Checkpoint and Kinetochore Motor Proteins in Breast Cancer Cells as Targets for the Development of Novel Anti-Mitotic Drugs. Defense Technical Information Center, 2004. http://dx.doi.org/10.21236/ada428246.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany rozszerzonymi bibliografiami na temat „Anti-breast cancer drug” dla poszczególnych typów źródeł:
Artykuły w czasopismach Rozprawy doktorskie
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii